2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
19
Endometrial Neoplasms
15
Ovarian Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
7
Squamous Cell Carcinoma of Head and Neck
6
Uterine Cervical Neoplasms
5
Head and Neck Neoplasms
5
Breast Neoplasms
5
Rectal Neoplasms
4
Pancreatic Neoplasms
4
Melanoma
4
Lung Neoplasms
4
Colonic Neoplasms
4
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Osteosarcoma
2
Multiple Myeloma
2
Locally Advanced Rectal Cancer (LARC)
2
Carcinoma, Renal Cell
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Turcot syndrome
1
Interventions
Drug Therapy
3
Temozolomide
2
Radiotherapy
2
Radiosurgery
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
sacubitril and valsartan sodium hydrate drug combination
1
icotinib
1
dostarlimab
1
beta Carotene
1
avelumab
1
alpha-Tocopherol
1
Varenicline
1
Tyrosine Kinase Inhibitors
1
Trastuzumab
1
Tobacco Use Cessation Devices
1
Therapeutics
1
Thalidomide
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Semen Analysis
1
Registries
1
Probiotics
1
Patient Reported Outcome Measures
1
Panitumumab
1
Nicotine Chewing Gum
1
Myofascial Release Therapy
1
Megestrol Acetate
1
Lenalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Second Primary
×
dostarlimab
×
Clear all
NCT05855811
2024-07-15
PREDOSTAR
Centre Leon Berard
Phase 2
Recruiting
400 enrolled